The Monarch eTNS System is indicated for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications. The device is used for patient treatment by prescription only and is intended to be used in the home under the supervision of a caregiver during periods of sleep.
The most common side effects observed with eTNS use are: drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue. No serious adverse events have been associated with use of the device. Please consult the instructions for use for additional information.
Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed neurological conditions in school-age children that often persists into adulthood. Parents and caregivers looking for alternatives to ADHD medication have a new treatment option: The Monarch eTNS (external Trigeminal Nerve Stimulation) System by NeuroSigma.
Getting the Monarch eTNS System
The Monarch eTNS System is now available to patients and physicians through NeuroSigma’s Early Access Program. There are two ways to obtain a device.
If you would like to work with your existing doctor or healthcare professional, simply download our PATIENT INFORMATION FORM. This download contains the Monarch eTNS prescription form for you to share with your healthcare professional and step-by-step instructions on how to get the device.